1,1'-Carbonyldiimidazole → tert-Butyl (S)-3-(6-tert-butoxycarbonylaminopyridin-3-yl)-2-[3-((8S,11R)-8-isopropyl-10-oxo-6-oxa-1,9,14-triazabicyclo[11.2.1]hexadeca-13(16),14-dien-11-yl)ureido]propionate

HRID 2040013ノート

反応式

HRID 2040013 の反応式
[NH2:1][C@@H:2]1[CH2:16][C:15]2=[CH:17][N:12]([CH:13]=[N:14]2)[CH2:11][CH2:10][CH2:9][CH2:8][O:7][CH2:6][C@H:5]([CH:18]([CH3:20])[CH3:19])[NH:4][C:3]1=[O:21].[C:22](N1C=CN=C1)(N1C=CN=C1)=[O:23].[NH2:34][C@@H:35]([CH2:43][C:44]1[CH:45]=[N:46][C:47]([NH:50][C:51]([O:53][C:54]([CH3:57])([CH3:56])[CH3:55])=[O:52])=[CH:48][CH:49]=1)[C:36]([O:38][C:39]([CH3:42])([CH3:41])[CH3:40])=[O:37]>CN(C=O)C>[C:54]([O:53][C:51]([NH:50][C:47]1[N:46]=[CH:45][C:44]([CH2:43][C@H:35]([NH:34][C:22]([NH:1][C@@H:2]2[CH2:16][C:15]3=[CH:17][N:12]([CH:13]=[N:14]3)[CH2:11][CH2:10][CH2:9][CH2:8][O:7][CH2:6][C@H:5]([CH:18]([CH3:19])[CH3:20])[NH:4][C:3]2=[O:21])=[O:23])[C:36]([O:38][C:39]([CH3:40])([CH3:41])[CH3:42])=[O:37])=[CH:49][CH:48]=1)=[O:52])([CH3:57])([CH3:56])[CH3:55]

参加物

5

実験手順

A solution of 56 mg (190 μmol) of (8S,11R)-11-amino-8-isopropyl-6-oxa-1,9,14-triazabicyclo[11.2.1]hexadeca-13(16),14-dien-10-one from step D in 5 ml of DMF was cooled to 0° C. and, while stirring, 32 mg (194 μmol) of 1,1′-carbonyldiimidazole were added. The mixture was stirred for 30 min, and then 64 mg (190 μmol) of tert-butyl (S)-2-amino-3-(6-tert-butoxycarbonylaminopyridin-3-yl)propionate were added, and the mixture was warmed to RT. After standing overnight, the same amount of 1,1′-carbonyldiimidazole was again added, and the mixture was stirred for a further 24 h. It was then concentrated and purified by preparative HPLC. 27 mg of the desired compound were obtained.

後処理

  1. stirringThe mixture was stirred for 30 min
  2. stirringthe mixture was stirred for a further 24 h
  3. concentrationIt was then concentrated
  4. custompurified by preparative HPLC

出典と根拠

ORDレコード
ord-5df4e8c207a4497c960369da981fa846
出典データセット
uspto-grants-2013_11
特許番号
US08580777B2

反応ノート

読み込み中…